Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for the XeriJect drug delivery technology, aimed at developing, manufacturing, and commercializing a subcutaneous formulation of its orphan drug Tepezza (teprotumumab). The XeriJect suspensions enable concentrations exceeding 400 mg/ml, which helps to reduce injection volumes, lessen treatment burden, and enhance patient adherence.
As part of the agreement, Xeris is set to receive up to $75 million in development and regulatory milestone payments, along with potential additional sales milestone payments and royalties. Tepezza is approved for the treatment of thyroid eye disease (TED) and was acquired by Amgen last year through its purchase of Horizon Therapeutics.- Flcube.com
